Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  abemaciclib
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-8 of 8 for your search:
Start Over
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15362, I3Y-MC-JPBL, 2013-004728-13, NCT02107703
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15296, I3Y-MC-JPBK, 2013-004662-33, NCT02152631
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15417, I3Y-MC-JPBM, 2014-001502-18, NCT02246621
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the Brain
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15450, I3Y-MC-JPBO, NCT02308020
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15805, I3Y-MC-JPBY, 2014-005486-75, NCT02441946
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15252, I3Y-MC-JPBH, NCT02057133
A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15266, I3Y-MC-JPBJ, NCT02079636
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15573, I4X-MC-JFCU, NCT02411591
Start Over